hotspot -WSS

hotspot

author：explore 2025-10-02 18:49:55 - browse：9

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.

The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled.

The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Kaiser's Risant Health gobbled up Geisinger. Who is next?

hotspot

WSS

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Inari Medical to buy amputation prevention company LimFlow

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Ionis drug prevents swelling attacks due to hereditary angioedema

Coloradans with cystic fibrosis could lose access to Trikafta

explore

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

leisure time

As demand for Covid shots wanes, Moderna seeks its next success

With trial win, GSK could get blood cancer drug back on market

Continuity nursing helped my family in our darkest PICU moments

BMI, flaws aside, is found to be useful estimate of body fat in youth

Anesthesiologist group: stop taking Ozempic before surgery

At ASCO, AstraZeneca reports strong data for breast cancer drug

Apple is now the first public company to be valued at $3 trillion

Key Senate panel to consider PBM, drug pricing reform package

In Memoriam: Notable people who died in 2023

Brain injuries and the importance of a second opinion

focus

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Key Senate panel to consider PBM, drug pricing reform package

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Travis Kelce and the trap of celebrity vaccine endorsements

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Wikipedia

hotspot

hotspot

entertainment